U01CA294539

From perceptions to behaviors: A comprehensive approach to examine the impact of public health communication messaging about the continuum of risk for tobacco products - Project summary.

Effective communication strategies are urgently needed to convey the relative risks of tobacco products accurately among adults who currently use combustible tobacco while minimizing such appeal among youth populations.

There is a significant gap in research on the impacts of communicating the continuum of tobacco products risks to diverse audiences.

Current research has primarily been limited to cross-sectional studies of single message exposures among adults.

As such, there is insufficient evidence on how messaging about the continuum of risk of tobacco products would influence the message response, receptivity, behavioral precursors, and tobacco use behaviors among the diverse audiences that these messages must reach.

The long-term objective of this project is to optimize future public health communication on the continuum of risk for tobacco products to minimize tobacco use harms among adults who use tobacco products and prevent youth initiation and progression of tobacco product use.

Our proposed project, in direct response to RFA-OD-23-021, will assess the effects of FDA tobacco product risk continuum messaging on adult users of combustible tobacco products (including those who have not yet been able to quit) and youth/young adults using an integrated study design that captures the full range of relevant outcomes, from immediate message response and receptivity to longer-term behavior.

This project is guided by a theoretical framework integrating key constructs in health communication (Message Impact Framework), persuasion (McGuire's Persuasion Framework), behavioral economics, and behavioral change theories (Reasoned Action).

Our specific aims are to:

(1) Generate rankings of messages and identify effective message features based on perceived message effectiveness and message comprehension;

(2) Characterize effects of messages and message features on response and receptivity, and precursors to behavior, including behavioral intentions; and

(3) Specify immediate and long-term behavioral effects of tobacco product risk continuum messages.

Approach: We will deploy a nimble framework to: refine messaging and develop control messages (message rating survey, cognitive interviews); formally test message response, receptivity, and effects on behavioral precursors (online national experiments, eye-tracking and neuroimaging); and assess immediate and long-term effects on behavior (mobile device-based message delivery and laboratory smoking topography studies) among samples of adults who use combustible tobacco, youth/young adults who use non-combustible tobacco, and youth/young adults who do not use tobacco.

Impact: The successful completion of this project will provide FDA with clear, rigorous, and comprehensive evidence regarding the effectiveness of the specific messages provided for this study, as well as theory-informed insights regarding broader message strategies to optimize future public health communication on the continuum of risk for tobacco products to diverse audiences.

The Johns Hopkins University

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.077 - Family Smoking Prevention and Tobacco Control Act Regulatory Research

National Cancer Institute (NCI) [HHS - NIH]

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Baltimore, Maryland 212182608 United States

Single Zip Code

Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required) (RFA-OD-23-021)

Amendment Since initial award the total obligations have increased 95% from $2,490,060 to $4,855,315.